2 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow taladegib: new trials by email Literature Review of taladegib trials Research Report on taladegib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 213 | 2024-11-15 | 2026-11-17 |
| A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) taladegib, placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 41 | 2021-08-26 | 2024-12-02 |
| Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer Carboplatin, External Beam Radiation Therapy, Laboratory Biomarker Analysis - Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7 | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 7 | 2017-03-07 | 2023-07-10 |
Idiopathic Pulmonary Fibrosis (2) · Pulmonary Fibrosis (2) · Adenocarcinoma Of Esophagus (1)
Endeavor Biomedicines, Inc. (2) · M.D. Anderson Cancer Center (1)
Australia (2) · Canada (2) · Malaysia (2) · Mexico (2) · South Korea (2) · Argentina (1) · Austria (1) · Belgium (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · New Zealand (1) · United Kingdom (1) · United States (1)
Jaffer A Ajani (1) · John Huetsch, M.D. (1) · Lisa Lancaster, M.D. (1)